Calamos Advisors
MRNA icon

Calamos Advisors’s Moderna MRNA Stock Holding History

Calamos Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-80,521
Closed -$9.52M – 1292
2022
Q3 		$9.52M Hold
80,521
– – 0.04% 503
2022
Q2 		$11.5M Buy
80,521
+2,169
+3% +$310K 0.05% 444
2022
Q1 		$13.5M Buy
78,352
+10,443
+15% +$1.76M 0.05% 423
2021
Q4 		$17.2M Buy
+67,909
New +$19.9M 0.06% 310
2020
Q3 		– Sell
-10,364
Closed -$665K – 733
2020
Q2 		$665K Buy
+10,364
New +$568K ﹤0.01% 668

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Calamos Advisors's MRNA Position: Q4 2022 in Review

Calamos Advisors sold out of Moderna (MRNA) in Q4 2022, closing a stake of 80,521 shares — an estimated $9.52M sold.

Calamos Advisors first reported a position in MRNA in Q2 2020 and held it in 5 quarters. The position peaked at $17.2M in Q4 2021. 1,071 funds tracked by Wall St. Rank hold MRNA as of Q4 2022.

  • Calamos Advisors reported no remaining Moderna position as of Q4 2022 after selling out during the quarter.
  • Calamos Advisors sold 80,521 Moderna shares in Q4 2022, an estimated $9.52M.
  • Calamos Advisors first reported a position in Moderna in Q2 2020 and held it in 5 quarters.
  • Calamos Advisors's Moderna position peaked at $17.2M in Q4 2021.
  • 1,071 funds tracked by Wall St. Rank held Moderna as of Q4 2022.

Based on Calamos Advisors's 13F filing for Q4 2022, filed 26 Jan 2023.